Keywords: µep; electrophoretic mobility; ACE; affinity capillary electrophoresis; Akt; protein kinase B; BGE; background electrolyte; BZM; benzamidine hydrochloride; CE; capillary electrophoresis; DMSO; dimethyl sulfoxide; EMMA; electrophoretically mediated microa
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Fragment-based drug discovery; Affinity capillary electrophoresis; Binding assay; Weak interaction drug-target; % inh; percentage of inhibition; μep; electrophoretic mobility; ACE; affinity capillary electrophoresis; AGB; 4-acetamidophenyl 4-guanidinoben
Keywords: Cyps; cyclophilins; CypA; cyclophilin A; PPIases; peptidyl-prolyl isomerases; CsA; cyclosporin A; HIV-1; human immunodeficiency virus 1; HCV; hepatitis C virus; SBDD; structure-based drug design; FBDD; fragment-based drug discovery; MD; molecular dynami
Keywords: HIV; human immunodeficiency virus; TB; tuberculosis; FBDD; fragment-based drug discovery; HTS; high-throughput screening; SPR; surface plasmon resonance; Mtb; Mycobacterium tuberculosis; Mab; Mycobacterium abscessus; INH; isoniazid; PZA; pyrazinamide; NTM
Capillary electrophoresis in the context of drug discovery
Keywords: ACE; affinity capillary electrophoresis; AGP; α-acid glycoprotein; AH; adrenaline hydrochloride; AIμEA; automatic micro-enzyme assay; AL; amlodipine; AT; antithrombin III; Bag3; Bcl2-associated anthanogene 3; BGE; background electrolyte; CM; chylomicron
Keywords: X-ray crystallography; Fragment screening; HIV; Influenza; BpGCDH; B. pseudomallei glutaryl-CoA dehydrogenase; DHNA; 7,8-dihydroneopterin aldolase; DMSO; dimethylsulfoxide; FBDD; fragment-based drug discovery; HCV; hepatitis C virus; HIV; human immunodef
Keywords: DENV; Dengue virus; NS; non-structural protein; MTase; methyltransferase; Hel; helicase; AdoMet; S-adenosyl-l-methionine; AdoHcy; S-adenosyl-l-homocysteine; FBDD; fragment-based drug discovery; FBS; fragment-based screening; FBS-X; FBS by X-ray crystallog
Keywords: MAP Kinase Kinase 3 (MKK3); MAP Kinase Kinase 6 (MKK6); FBDD
Fragment-based discovery of a potent NAMPT inhibitor
Keywords: NMR; Fragment-based; FBDD; FBLD; NAMPT;
N-Acylhydrazones as drugs
Keywords: ADME; absorption, distribution, metabolism, excretion; BBNH; N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone; BISH; boronyl salicylaldehyde isonicotinoyl hydrazone; DB; drug bank; DHBNH; dihydroxy benzoyl naphthyl hydrazone; FDA; food and dru
Fragment screening for drug leads by weak affinity chromatography (WAC-MS)
Keywords: 3-ABA; 3-aminobenzamidine; 4-ABA; 4-aminobenzamidine; AmAc; ammonium acetate; APCI; atmospheric pressure chemical ionization; AQP1; human aquaporin-1; BA; benzamidine; BCA; bicinchoninic acid; CMC; critical micelle concentration; DMSO; dimethyl sulfoxide;
New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV
Keywords: Bacterial gyrase; Topoisomerase IV; Drug resistance; Binding sites; Potency; DNA; deoxyribonucleic acid; ATP; adenosine triphosphate; GyrA; gyrase A subunit; GyrB; gyrase B subunit; ParC; topoisomerase IV C subunit; ParE; topoisomerase IV E subunit; PDB;
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents
Keywords: MAPK; RAF inhibitors; Anti-cancer agents; Abl; Abelson murine leukemia viral oncogene; ATP; Adenine triphosphate; Bcl-2; B-cell lymphoma; CNS; Central nervous system; COX-2; Cyclo-oxygenase enzyme-2; CR; Conserved region; CRD; Cysteine-rich domain; DFG; A
Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups
Keywords: BRD4; BI2536; Indoline; WPF binders; c-Myc; PD-L1; BCPs; Bromodomain-containing proteins; BET; bromodomain and extra-terminal; BRD4-BD1; first bromodomain of BRD4; CREB; cyclic-AMP response element binding protein; FA; fluorescence anisotropy; FBDD; fragm
Application of the fragment molecular orbital method analysis to fragment-based drug discovery of BET (bromodomain and extra-terminal proteins) inhibitors
Keywords: FMO; FBDD; PPIs; Bromodomain inhibitor; CH/Ï interaction;
Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design
Keywords: Phenyl [(phenylcarbamoyl)amino]benzene-1-sulfonate derivatives; N-Phenyl-[(phenylcarbamoyl)amino]benzene-1-sulfonamide derivatives; Fragment-linking strategy; Dengue virus; NS5 methyltransferase inhibitors; Antiviral activity; DENV; dengue virus; NS; non-
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1
Keywords: FBDD; Fragment-based drug discovery; MetAP2; Methionine aminopeptidase 2; Metalloprotease; Indazole;
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2
Keywords: Methionine aminopeptidase-2; MetAP2; Metalloprotease; Fragment-based drug discovery; FBDD; Structure-based drug design; SBDD; Pyrazolo[4,3-b]indoles;
The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor
Keywords: PAK4; Inhibitor; FBDD; Cancer; Drug discovery;
Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design
Keywords: Tyk2; Inhibitor; Water-ring analysis; FBDD; STATs activation
A fluorescent approach for identifying P2X1 ligands
Keywords: Fluorescent; Ligand binding; Ligand gated ion channel; P2X1; Fragment-based drug discovery; Pharmacology; NF449; Alexa-647; FBDD; Fragment-based drug design; ATP; Adenosine triphosphate; SCA; Scaffold classification approach;
Identification of anthranilamide derivatives as potential factor Xa inhibitors: Drug design, synthesis and biological evaluation
Keywords: Factor Xa; FBDD; Structure-based pharmacophore; Consensus docking; Prothrombin time; Anticoagulant;
Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein
Keywords: NMR; Fragment-based; FBDD; FBLD; Apoptosis; BCL; MCL-1;
Towards novel therapeutics for HIV through fragment-based screening and drug design
Keywords: FBDD; Allosteric sites; HIV-1; Fragment-based screening;
Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors
Keywords: Rho kinase; ROCK-I; ROCK inhibitors; Fragment-based drug discovery; FBDD; STD NMR;
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916
Keywords: Aurora inhibitors; BEI; Lead generation; FBDD; FACS; Cellular phenotype
Fragment-based discovery and optimization of BACE1 inhibitors
Keywords: BACE1; Alzheimer’s disease; FBDD; SPR; Crystallography; 2-Aminobenzimidazole
The rational design of a novel potent analogue of the 5′-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity
Keywords: Fragment-based drug design; FBDD; 5′-AMP-activated protein kinase; AMPK; Compound C
A fluorescence correlation spectroscopy-based assay for fragment screening of slowly inhibiting protein–peptide interaction inhibitors
Keywords: FCS; Protein–protein interaction inhibitor; FBDD; Fragment screening
Structure-guided expansion of kinase fragment libraries driven by support vector machine models
Keywords: FBDD; fragment-based drug design; SBDD; structure-based drug design; QSAR; quantitative structure activity relationship; SVM-FP; support vector machine-fingerprints; PPV; positive predicted value; LE; ligand efficiency; HAC; heavy atom count; AMW; atomi
Ligand- and substrate-based 19F NMR screening: Principles and applications to drug discovery
Keywords: ALARM; a La assay to detect reactive molecules; BEI; binding efficiency index; CPMG; Carr-Purcell-Meiboom-Gill; CSA; chemical shift anisotropy; ERETIC; electronic reference to access in vivo concentrations; FA; fluorescence anisotropy; FABS; fluorin